cardiovascular disease (CVD)
Conditions
Interventions
None listed
Sponsors
Amsterdam UMC
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Adult male or female, age >=50 years - Prior to start therapy - Confirmed diagnosis of cancer: - Treatment-naive advanced esophageal, gastric, or gastro-esophageal cancer planned for first-line nivolumab or chemotherapy only or follow-up only after resection - Treatment-naive advanced colorectal cancer planned for first-line pembrolizumab or other systemic therapies - Recurrent or metastatic head/neck squamous cell carcinoma with disease progression during platinum-based chemotherapy who are planned for pembrolizumab or other systemic therapies - Non-small-cell lung carcinoma planned for pembrolizumab or durvalumab or other systemic therapies - Advanced renal cell carcinoma planned for first-line ipilimumab/nivolumab or other systemic therapies - Inresectible or advanced melanoma planned for ipilimumab/ nivolumab
Exclusion criteria
Exclusion criteria: • ICI therapy in previous 12 months; • Suspected or confirmed viral, fungal, or bacterial infectious disease; • Use of immunosuppressive therapy prior to ICI start; • Estimated glomerular filtration rate (eGFR)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary parameter: absolute total coronary plaque volume progression | — |
Secondary
| Measure | Time frame |
|---|---|
| Secundary parameters: - CCTA (coronair): plaque progression and plaque characteristics (vulnerability) - CTA carotid): plaque progression and plaque characteristics (vulnerability) - Clinical outcomes: cardiovacular disease events (i.g. myocardial infarction, stroke), venous thromboembolism, immune related adverse events, death of any cause | — |
Countries
Netherlands
Contacts
Public ContactA Strijdhorst
Amsterdam UMC
Outcome results
None listed